急性间质性肾炎 中国就医指南

Acute Interstitial Nephritis (AIN) is an immune-mediated inflammatory disorder primarily affecting the renal interstitium and tubules, leading to abrupt deterioration in kidney function. Characterized by interstitial edema, inflammatory cell infiltration (predominantly lymphocytes, eosinophils, and plasma cells), and tubular injury, AIN typically presents with acute kidney injury (AKI), often accompanied by systemic symptoms such as fever, rash, arthralgia, and peripheral eosinophilia—collectively termed the 'classic triad' (though present in only ~10–15% of cases). Pathogenesis involves T-cell–driven hypersensitivity reactions triggered by exogenous antigens—most commonly medications—including NSAIDs, proton pump inhibitors (PPIs), antibiotics (e.g., beta-lactams, fluoroquinolones), and diuretics. Less frequently, AIN arises from autoimmune conditions (e.g., Sjögren’s syndrome, systemic lupus erythematosus), infections (e.g., streptococcal, Legionella, H. pylori), or idiopathic causes. The inflammatory cascade results in tubulointerstitial damage, impaired solute transport, and reduced glomerular filtration rate (GFR), sometimes progressing to chronic kidney disease if diagnosis or intervention is delayed. Epidemiologically, AIN accounts for 10–15% of all biopsy-proven AKI cases in adults and is more prevalent among older adults (median age 60–70 years), with a slight male predominance. Drug-induced AIN represents over 70% of cases, with PPIs now surpassing NSAIDs as the most common offending agents in many cohorts. Key risk factors include polypharmacy, advanced age, preexisting chronic kidney disease, and genetic susceptibility (e.g., HLA-DRB1*07:01 allele linked to PPI-associated AIN). Importantly, early recognition is critical: untreated AIN may lead to irreversible fibrosis and permanent renal impairment. Quality of life is significantly impacted—not only due to fatigue, nausea, fluid retention, and cognitive fog associated with uremia but also from prolonged diagnostic uncertainty, treatment-related side effects (e.g., corticosteroid-induced insomnia, hyperglycemia, mood changes), and occupational or social disruption during recovery. Patients often experience anxiety about long-term kidney health, dialysis dependency, and medication restrictions. Timely discontinuation of the inciting agent and initiation of immunosuppression markedly improve outcomes; however, residual renal dysfunction occurs in ~20–40% of patients, necessitating ongoing nephrology follow-up and lifestyle modification. Multidisciplinary support—including dietary counseling, psychological services, and patient education on drug safety—is integral to holistic management and sustained functional recovery.

# 急性间质性肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：早期确诊、肾功能轻中度受损（eGFR ≥30 mL/min/1.73m²）、明确药物诱因且已停用者。

• •基础治疗：严格停用可疑药物（NSAIDs、PPI、抗生素等）+ 充分水化 + 避免肾毒性物质
• •糖皮质激素治疗（一线）：泼尼松0.5–1.0 mg/kg/d×2–4周，逐步减量至8–12周停药

• •检查检验费（必查）：尿常规+尿沉渣、血肌酐/eGFR、电解质、ANCA/ANA、肾脏超声、24h尿蛋白定量、血清IgG4（疑淋巴瘤或IgG4-RD时）——¥860–¥2,100

二、肾脏穿刺活检（核心诊断与评估手段）

适用条件：临床诊断不明确、肾功能快速恶化（eGFR下降>50%）、激素治疗无效或需排除其他肾病。

• •术前检查：凝血功能、血小板计数、双肾B超（确认解剖结构）——¥320–¥650
• •活检操作费+病理检查（光镜+免疫荧光+电镜）：¥4,200–¥7,800（含穿刺耗材、组织学及免疫组化）

三、特殊复杂情况处理

• •急性肾损伤需RRT支持（如少尿/无尿、高钾、肺水肿）：连续性肾脏替代治疗（CRRT）首日¥4,500–¥6,800，后续每日¥3,200–¥5,000
• •激素抵抗型（4周无效）：加用环磷酰胺或霉酚酸酯，联合治疗总药费¥2,600–¥9,500/3个月
• •合并严重过敏/血管炎表现：静脉甲泼尼龙冲击（3天），费用¥1,800–¥3,600（含药品+监护）

四、方案快速选择指南

• •预算有限、轻症初发者：首选停药+口服激素+基础检查（总预算≈¥2,000–¥4,000）
• •诊断存疑或进展迅速者：立即行肾活检+激素治疗（总预算≈¥6,000–¥12,000）
• •已透析或合并多系统受累者：CRRT+免疫抑制强化方案（首月预算≈¥25,000–¥45,000）